World Conference on Lung Cancer 2026 Intelligence Report

WCLC 2026 Conference Intelligence Report

Beacon’s analysts have screened the World Conference on Lung Cancer (WCLC) 2026 abstract programme, identifying and analysing 245 drug- and trial-relevant abstracts to help you quickly focus on the developments shaping the future of lung cancer treatment.

The WCLC 2026 Conference Intelligence Report highlights the standout abstracts being presented at the congress and reveals the most important drug, target and clinical trial trends emerging across the lung cancer landscape. From PD-1/PD-L1 multi-specific antibodies and first-in-human programmes to primary trial analyses and late-phase clinical readouts, the report delivers a clear, data-driven view of the innovations advancing lung cancer therapeutics.

Download The WCLC 2026 Conference Intelligence Report

The Report Includes:

Analysis of the most important PD-1/PD-L1 multi-specific programmes, including novel bispecific and trispecific antibody approaches entering clinical development.
A dedicated review of first-in-human abstracts, spotlighting emerging assets such as an EGFR/c-MET bispecific ADCs, ENPP1 inhibitor and HER2-targeted programme.
Insights into evolving drug, target and modality trends, including the growing prominence of bispecific antibodies, ADCs and biomarker-defined NSCLC populations.
Key late-phase and primary analysis readouts across NSCLC and SCLC with the potential to influence future treatment practice.
Links to all cited abstracts are included throughout the report.

Download Report

You May Also Be Interested In…

Oncology H1 2026 Landscape Review

Access Review

ASCO 2026 Highlights: Where Oncology is Moving Next

View Infographic

T-Cell Engager Patents: Commercial Activity and Innovation Insights

View Infographic

View All

Learn More About Oncology

What is Beacon Oncology?

The Most Comprehensive Way to Search the Oncology Drug Development Landscape: Unique search ontologies based on Oncology drug and trial characteristics
Market Leading Approach to Oncology Preclinical & Clinical Data Curation: Manual curation of key Oncology research and development data points by Oncology research scientists
Seamlessly Integrate Commercial & Scientific Data all in One Place: Search Oncology company and deal data based on their pipeline and technologies.
Unrivalled Granularity in Reports & Analysis: Our search ontology and technology indexing enable comprehensive analysis not seen elsewhere.

Learn More About Beacon Oncology Request Demo

What is Beacon?

Beacon is the essential intelligence platform for R&D decision-makers working in pharma and biotech, offering unique technology and drug datasets for complex therapeutics and disease areas.

Our market-defining proprietary ontologies, manual data curation, and accurate and comprehensive life science data, provide our customers with unparalleled visibility of the drug, trial and commercial landscape.

This is why 24 of the top 25 pharmaceutical companies trust Beacon to power their critical pipeline, competitive, and commercial decisions.

We’d welcome the opportunity to show you how Beacon can transform your data strategy. Book your personalized demonstration today!

Request Demonstration